Cantor Fitzgerald Reiterates Overweight Rating on Johnson & Johnson (JNJ) Ahead of 1Q Report

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. FISV
10. CVS

Go back to Cantor Fitzgerald Reiterates Overweight Rating on Johnson & Johnson (JNJ) Ahead of 1Q Report

Fate Therapeutics (FATE) Announces Pact with Janssen (JNJ) for Novel iPSC-derived Cell-based Cancer Immunotherapies

April 2, 2020 4:54 PM EDT

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today a global collaboration and option agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Under the multi-year collaboration agreement, Janssen will contribute proprietary antigen binding domains for up to four tumor-associated antigen targets. The Company will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product... More

Johnson & Johnson (JNJ) PT Lowered to $150 at Wells Fargo

April 2, 2020 6:43 AM EDT

Wells Fargo analyst Larry Biegelsen lowered the price target on Johnson & Johnson (NYSE: JNJ) to $150.00 (from $165.00) while maintaining a Overweight rating.... More